New study show that ProGo™ significantly reduces BMI

Hofseth BioCare ASA's new study on the effects of HBCs salmon protein ProGo™ has been accepted for publication in the Journal of Obesity & Weight Loss Therapy in USA.

The article titled “A Placebo-Controlled, Randomized Study on the Impact of Dietary Salmon Protein Hydrolysate Supplementation on Body Mass Index in Overweight Human Subjects”, shows that a daily dietary intake of 16 g of HBCs salmon protein hydrolysate for 42 days, statistically significantly reduced Body Mass Index by 5.6 % in overweight subjects, in comparison with whey protein isolate as a placebo-control.

Four metabolism-relevant serum biomarkers - bile acid, interleukin-6, Preheparin lipoprotein lipase mass and adiponectin - were also positively impacted using one-tailed, paired student t-test analysis, leading  to the proposed metabolism-elevating mode-of-action. Diet and exercise levels were maintained for each subject as per their normal levels.

HBC has already started further research to identify the active individual peptide components in ProGo™ in terms of specific biological activity for obesity control. Salmon protein hydrolysate powder in supplemental doses may be a useful tool in the long-term management of obesity.

"Obesity is a major global health problem with over 3 million adults dying each year from obesity related complications. Overweight and obese individuals with abnormal or excessive fat accumulation are at increased risk of type-2 diabetes, cardiovascular disease and metabolic disorders, particularly cancer," says Dr. Bomi Framroze, Chief Scientific Officer at Hofseth BioCare ASA.


Read the entire article here.
ProGo can be purchased at as ENDURANCE Protein.